CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotech company specializing in regRNA-targeting antisense oligonucleotide (ASO) therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President & CEO, Josh Mandel-Brehm, will deliver a corporate update presentation on Wednesday, January 15, 2025, at 3:45 p.m. PST in San Francisco, California.

The presentation will be available through a live webcast on CAMP4's investor relations website. Interested parties can access the webcast at www.investors.camp4tx.com, and a replay will remain available on the company's website for 30 days after the conference.

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43^rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15, 2025, at 3:45 p.m. PST.

The event will be webcast live and can be accessed on the investor relations page of CAMP4’s website at www.investors.camp4tx.com. A replay of the webcast will be archived on the CAMP4 website for 30 days following the conference.

About CAMP4 Therapeutics

CAMP4 is developing disease-modifying treatments for a broad range of rare and prevalent genetic diseases where increasing healthy protein levels may offer meaningful therapeutic benefits. Our approach allows for targeted gene upregulation by harnessing a fundamental mechanism of how genes are controlled. To increase gene expression, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X.

Contacts

Investor Relations:
Sandya von der Weid
LifeSci Advisors
svonderweid@lifesciadvisors.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

When is CAMP4's presentation at the 2025 J.P. Morgan Healthcare Conference?

CAMP4 will present on Wednesday, January 15, 2025, at 3:45 p.m. PST in San Francisco, California.

How can investors watch CAMP4's J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on CAMP4's investor relations website at www.investors.camp4tx.com.

How long will CAMP4's J.P. Morgan Conference presentation replay be available?

The webcast replay will be archived on CAMP4's website for 30 days following the conference.

What type of therapies is CAMP4 (CAMP) developing?

CAMP4 is developing regRNA-targeting antisense oligonucleotide (ASO) therapies aimed at upregulating gene expression to restore healthy protein levels.